Skip to content
Clinical Trials – home
Therapeutic area

Eye disorders – page 28

  • 373 clinical trials
  • 123 recruiting
  • 138 conditions
  • 27 countries

Conditions in this area

138 conditions with trials, the busiest first

Clinical trials in Eye disorders

373 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

373 clinical trials

Dry eye+1

Not recruiting

Study on the Effectiveness and Safety of Ianalumab for Patients with Active Sjögren’s Syndrome

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Ianalumab
  • Sponsor:Novartis Pharma AG

Dry eye+1

Not recruiting

Study on the Effectiveness and Safety of Ianalumab for Patients with Active Sjögren’s Syndrome

Registered drug
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Ianalumab
  • Sponsor:Novartis Pharma AG

Conjunctivitis allergic+1

Not recruiting

Study on the Effectiveness and Safety of Allergenic Extract of Olea Europaea Pollen for Patients with Moderate-to-Severe Olive Pollen Allergy

Registered drug
Countries:SpainSpain
  • Participants:18–64 years
  • Substances:Loratadine
  • Sponsor:ROXALL Medizin GmbH

Study on Batoclimab for Patients with Thyroid Eye Disease

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Batoclimab
  • Sponsor:Immunovant Sciences GmbH

Study on the Effectiveness and Safety of Ranibizumab for Patients with Wet Age-Related Macular Degeneration Using a 36-Week Refill System

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:65+ years
  • Substances:Ranibizumab
  • Sponsor:F. Hoffmann-La Roche AG

Colour blindness

Not recruiting

Study on the Safety and Effectiveness of rAAV.hCNGA3 for Adults and Minors with CNGA3-Linked Achromatopsia

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Adeno-Associated Viral Vector Serotype 8 Containing The Human Cnga3 Gene Under The Control Of A Cone Arrestin Promoter
  • Sponsor:Universitaetsklinikum Tuebingen AöR

Open angle glaucoma

Not recruiting

Study on the Effectiveness of Bimatoprost SR for Patients with Open-Angle Glaucoma or Ocular Hypertension

InvestigationalNo placebo
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Bimatoprost
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Optic atrophy

Not recruiting

Study on the Safety and Effects of Nicotinamide for Patients with Dominant Optic Atrophy

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Nicotinamide
  • Sponsor:Centre Hospitalier Universitaire D'Angers

Study on the Effectiveness and Safety of OCS-01 Eye Drops with Dexamethasone for Patients with Diabetic Macular Edema

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Dexamethasone
  • Sponsor:Oculis Operations S.a.r.l.

Seasonal allergy

Not recruiting

Study on the Effectiveness and Safety of Phleum Pratense Pollen Extract for Patients with Moderate-to-Severe Grass Pollen Allergy

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Loratadine
  • Sponsor:ROXALL Medizin GmbH

Graves' disease

Not recruiting

Study on the Effects of Satralizumab for Patients with Moderate-to-Severe Thyroid Eye Disease

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Sponsor:F. Hoffmann-La Roche AG

Dry eye+1

Not recruiting

Study on Long-Term Safety and Efficacy of Ianalumab for Patients with Sjögren’s Syndrome

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Emtricitabine
  • Sponsor:Novartis Pharma AG

Substances studied in this area

The therapies tested most often in Eye disorders trials.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.